Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT07244341 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT07244341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07244341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter Trial Evaluating the Safety, Tolerability, and Efficacy of Valemetostat (DS-3201) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Recruiting
Start date
December 3, 2025
Completion date
November 30, 2029
Enrollment
60 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer